WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Eye Health America
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Pharma Tech
Xeris | October 25, 2021
Xeris Biopharma Holdingsa biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced a collaboration agreement with Merck , with an option to license Xeris “We are quite excited to be working closely with Merck on this opportunity using our novel platform technology, XeriJect The XeriJect platform has broad applicability in improving the delivery of...
Nucleai and Sirona Dx | July 14, 2022
Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, and Sirona Dx, a leading provider of multiomic single-cell analytical services, today announced a collaboration to advance the discovery of novel spatial biomarkers in solid tumors. The partnership combines Nucleai’s powerful AI spatial analytics platform with Sirona Dx’s leading multiplex assay development expertise to identify novel spatial signatures in high-pl...
Business Insights, PHARMACY MARKET
Prnewswire | April 04, 2023
Endo International plc announced that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the authorized generic (AG) version of Merck's Noxafil® (posaconazole) 200 mg/5 mL oral suspension in the U.S. "Our partnership with Merck underscores our reputation as an industry-leading supplier," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. "This newly available Noxafil® AG do...
Huateng Pharma | February 11, 2020
This year is an unusual year due to the infection of the Novel Coronavirus Pneumonia (NCP) epidemic. Hunan Huateng Pharmaceutical Co., Ltd. (hereinafter referred to as Huateng), as a drug research and development company with rich experience in developing antiviral drugs, has attached close attention to this matter. Considering that there is no targeted medicine for novel coronavirus pneumonia (NCP) infection and that NCP virus is highly similar to SARS / Middle East Respiratory Syndrome (MERS) ...
Article
PHARMACY MARKET
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE